Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals plc (JAZZ) has issued a DEFA14A supplement to its 2025 proxy materials outlining a planned CEO succession and related compensation adjustments.
- Leadership transition: President & COO Renee Gala will become President & Chief Executive Officer on 11 Aug 2025. Current CEO Bruce Cozadd will remain until that date, then serve in a transition role through 12 Sep 2025 before retiring while continuing as Board Chair.
- Board expansion: Board size increases from 12 to 13 seats; Ms. Gala will join as a Class I director with a term expiring in 2027.
- Compensation changes: Ms. Gala’s annual base salary rises to $1.2 million (from $0.9 million) and her target cash bonus to 110% of salary (from 80%), effective 11 Aug 2025.
- Equity awards: One-time promotion grant valued at ~$6.5 million (33% RSUs, 67% PSUs) in addition to her previously granted 2025 annual equity award of ~$6 million.
- Enhanced severance: Cash severance on involuntary termination without cause (outside a change-in-control period) increases to 150% of base salary plus up to 18 months of COBRA premiums (previously 100% salary and 12 months premiums).
- Voting impact: No changes to the proposals or proxy card for the 24 Jul 2025 AGM; shareholders are encouraged to review both the original proxy and this supplement.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) disclosed in an 8-K that its Board appointed current President & COO Renee Gala as President & Chief Executive Officer effective 11 Aug 2025. The Board will expand from 12 to 13 members and seat Gala as a Class I director through the 2027 AGM. Outgoing CEO Bruce Cozadd will remain CEO until 11 Aug 2025, shift to a transition role until 12 Sep 2025, then retire while continuing as non-executive Chair.
Gala’s compensation package was revised: base salary rises 33 % to $1.2 million; target annual bonus increases to 110 % of salary (from 80 %). She will also receive a one-time $6.5 million promotion equity grant (33 % RSUs vesting annually over four years; 67 % PSUs tied to 2025 performance metrics) on top of her previously granted $6 million 2025 annual equity award.
Severance protections were enhanced: in an involuntary termination without cause outside a change-in-control window, Gala is now entitled to a lump-sum payment equal to 150 % of base salary (previously 100 %) and up to 18 months of company-paid COBRA premiums (previously 12 months).
No financial metrics, earnings guidance, or strategic updates were included. A confirming press release (Exhibit 99.1) was furnished under Item 7.01.